Phenomic is an early stage biotech company based out of Toronto, targeting disease micro-environments in cancer and fibrosis. By using a combination of automated microscopy, single cell sequencing, and machine learning Phenomic is able to screen targets in complex experimental models that better mimic the tumour microenvironment. Phenomic have also developed tools that let them map results back to human data, to ensure model relevance at the molecular level; a key challenge facing todays pipelines. To date we've used this platform to identify key targets in the tumour stroma, for our lead indication colorectal cancer. We're now working to commercialize these targets and push them into pre-clinical studies.